子宮内膜がんの市場規模、シェア、成長分析、がんタイプ別、治療法別、診断方法別、ステージ別、最終用途別、地域別 - 産業予測、2025～2032年

子宮内膜がんの世界市場規模は2023年に286億9,000万米ドルとなり、予測期間（2025-2032年）のCAGRは4.9%で、2024年の301億米ドルから2032年には441億3,000万米ドルに成長する見通しです。

世界の子宮内膜がん市場は、罹患率の上昇、意識の高まり、ヘルスケアインフラの強化に後押しされ、力強い成長を遂げています。分子プロファイリングや遺伝子検査を含む診断ツールの革新は、より正確で個別化された治療選択肢につながっています。治療成績の改善をもたらす標的療法、免疫療法、併用療法の出現により、市場はさらに拡大しています。ゲノム・プロファイリングやリキッドバイオプシーなどの進歩は、早期発見とオーダーメイドの治療アプローチを促進します。とはいえ、高い治療費、高度なヘルスケアサービスへの限られたアクセス、効果的な早期発見法の差し迫った必要性などの課題は、子宮内膜がんの世界の影響に対処する上で引き続き大きなハードルとなっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

子宮内膜がん市場規模：がんタイプ別

• 市場概要
• 子宮内膜がん
  • 腺がん
  • がん肉腫
  • 扁平上皮がん
  • その他の種類のがん
• 子宮肉腫

子宮内膜がん市場規模：治療法別

• 市場概要
• 手術
• 化学療法
• 放射線治療
• ホルモン療法
• 標的療法
• 免疫療法

子宮内膜がん市場規模：診断方法別

• 市場概要
• 生検
• 骨盤超音波検査
• 子宮鏡検査
• CTスキャン
• その他の診断方法

子宮内膜がん市場規模：ステージ別

• 市場概要
• ステージI
• ステージ II
• ステージIII
• ステージIV

子宮内膜がん市場規模：最終用途別

• 市場概要
• 病院
• がんセンター
• 外来手術センター

子宮内膜がん市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Notable Product：Keytruda（pembrolizumab）
• AstraZeneca plc（United Kingdom）
• Notable Product：Imfinzi（durvalumab）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol Myers Squibb Company（United States）
• Karyopharm Therapeutics Inc.（United States）
• Siemens Healthineers AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Incyte Corporation（United States）
• Context Therapeutics Inc.（United States）
• Evergreen Therapeutics, Inc.（United States）
• Sysmex Corporation（Japan）
• Gilead Sciences, Inc.（United States）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• Sanofi S.A.（France）

結論と推奨事項

Global Endometrial Cancer Market size was valued at USD 28.69 billion in 2023 and is poised to grow from USD 30.1 billion in 2024 to USD 44.13 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The global endometrial cancer market is experiencing robust growth, fueled by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic tools, including molecular profiling and genetic testing, are leading to more precise and personalized treatment options. The market is further expanding due to the emergence of targeted therapies, immunotherapies, and combination treatment modalities that provide improved outcomes. Advancements such as genomic profiling and liquid biopsies facilitate early detection and tailored treatment approaches. Nevertheless, challenges like high treatment costs, limited access to advanced healthcare services, and the pressing need for effective early detection methods continue to pose significant hurdles in addressing the global impact of endometrial cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segmental Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

The global endometrial cancer market is significantly driven by the rising incidence of this prevalent gynecological cancer. Factors such as obesity, hormonal imbalances, and diabetes are contributing to a steady increase in cases, prompting a growing need for effective diagnostic and therapeutic options. This heightened demand for solutions not only accelerates market growth but also emphasizes the importance of advancements in medical technology and enhanced screening methods. These innovations facilitate early detection and treatment of endometrial cancer, ultimately leading to improved patient outcomes and further stimulating investments in healthcare infrastructure to combat this escalating health concern.

Restraints in the Global Endometrial Cancer Market

One significant challenge facing the global endometrial cancer market is the combination of high treatment costs and restricted healthcare accessibility, particularly in developing countries. The financial burden associated with treatment options like surgeries, chemotherapy, and radiation therapy can be overwhelming for many patients, especially those lacking sufficient health insurance or financial resources. Furthermore, in various regions, inadequate healthcare infrastructure, including a shortage of diagnostic services and specialized professionals, complicates the timely and effective treatment of endometrial cancer. To enhance patient outcomes worldwide, it is essential to tackle these obstacles by improving both the affordability and accessibility of quality healthcare.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is experiencing a notable trend of increased collaborations and partnerships among pharmaceutical companies and research institutions, aimed at expediting drug development and clinical trials. This strategic synergy enhances the focus on innovative diagnostics and the introduction of novel therapeutic options, ultimately translating into improved patient outcomes. Moreover, the rising incidence of endometrial cancer and heightened awareness surrounding women's health are driving the demand for advanced treatment solutions. As stakeholders prioritize research investments and regulatory approvals, this collaborative landscape is likely to foster a dynamic market, positioning it for accelerated growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2025-2032)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2025-2032)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2025-2032)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations